First published 10/3/2026, 1:31:15 AM · Last updated 10/3/2026, 1:31:15 AM

MA01.04 Neoadjuvant PD-(L)1 Blockade in Combination With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

A journal article published by Elsevier BV reports on using PD-(L)1 blockade combined with chemotherapy as neoadjuvant treatment for borderline resectable and unresectable stage III non-small cell lung cancer. The source record provided is the article title and publisher with a 1 October 2025 publication date.

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 3/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 4/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 4/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The paper addresses a potential preoperative systemic therapy approach for advanced stage III non-small cell lung cancer.

Sources

MA01.04 Neoadjuvant PD-(L)1 Blockade in Combination With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

Report an issue